Healthy Weight, Lower Stress May Result In Fewer Changes Associated With Aging
Children With Recurrent Hodgkin’s Respond To Gemcitabine, Vinorelbine
Study Finds Moderate Alcohol Use By Women Associated With Increased Cancer Risk
Device Shortens Time To Make T Cells For Immunotherapy
Knowing Tumor Cell Structure Improves Treatment Decisions
Doctor-Patient Conversations At End of Life Associated With Lower Medical Expenses
Rituximab After CVP Improves Progression-Free Survival
Gene Delivery System Targets Tumor Blood Vessels In Dogs
FDA Approves Afinitor For Advanced Kidney Cancer
MEPACT Approved In Europe For Resectable Osteosarcoma
FDA Approves DNA Test For Two Types of HPV
NCI Cooperative Group, Cancer Center Trials Listed
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
